Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants

Documenti analoghi

• Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
  di: Hongxia Jia, et al.
  Pubblicazione: (2025)
• Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
  di: Matthias Hoch, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study
  di: Ramesh Boinpally, et al.
  Pubblicazione: (2024)
• Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects
  di: Martha Gonzalez, et al.
  Pubblicazione: (2025)
• Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case–Control Study
  di: Eugene Jeong, et al.
  Pubblicazione: (2025)